- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Planned Trial of Diabetes Drug Avandia Runs Aground
21 July 2010 4:39 pm
A large study to test the safety of the controversial diabetes drug Avandia has been put on partial hold by the Food and Drug Administration. The FDA held a hearing on the safety of Avandia last week. Some scientists argue that the drug persistently, if modestly, increases the risk of heart attacks in diabetes patients. But other scientists, as well as the drug's maker, GlaxoSmithKline, challenge those results. The TIDE trial was designed to clear up lingering doubts about the drug but would take at least 6 years to complete. And today, FDA informed Glaxo that it was not allowed to enroll any new patients in TIDE, although patients already enrolled can continue.
Science will report on the TIDE trial in the 23 July issue, which appears online tomorrow.